Paracetamol and cyclooxygenase inhibition: Is there a cause for concern?

Annals of the Rheumatic Diseases

Volumn 71, Issue 1, 2012, Pages 20-25

  Hinz, Burkhard ^a   Brune, Kay ^b  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 2; DICLOFENAC; IBUPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PLACEBO; PROSTAGLANDIN SYNTHASE INHIBITOR;

ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ASTHMA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DIASTOLIC BLOOD PRESSURE; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DOSE RESPONSE; DRUG CHOICE; DRUG DOSE COMPARISON; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG OVERDOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; ENDOTHELIUM; ENZYME ACTIVITY; ENZYME INHIBITION; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; LIVER TOXICITY; LONG TERM CARE; OSTEOARTHRITIS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; STOMACH INJURY; STROKE; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE AGGREGATION; THROMBOCYTE DYSFUNCTION;

ACETAMINOPHEN; ANALGESICS, NON-NARCOTIC; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASTHMA; BLOOD PLATELET DISORDERS; CARDIOVASCULAR DISEASES; CYCLOOXYGENASE 2 INHIBITORS; GASTROINTESTINAL DISEASES; HUMANS;

EID: 82955162596     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2011.200087     Document Type: Review

References (54)

1. Schnitzer TJ. Update of ACR guidelines for osteoarthritis: role of the coxibs. J Pain Symptom Manage 2002;23(4 Suppl):S24-30; discussion S31-4.
2. Botting RM. Mechanism of action of acetaminophen: is there a cyclooxygenase 3? Clin Infect Dis 2000;31(Suppl 5):S202-10. (Pubitemid 32291111)
3. Flower RJ, Vane JR. Inhibition of prostaglandin synthetase in brain explains the anti-pyretic activity of paracetamol (4-acetamidophenol). Nature 1972;240:410-11.
4. Graham GG, Scott KF. Mechanism of action of paracetamol. Am J Ther 2005;12:46-55. (Pubitemid 40516046)
5. Chandrasekharan NV, Dai H, Roos KL, et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci U S A 2002;99:13926-31. (Pubitemid 35215482)
6. Kis B, Snipes JA, Busija DW. Acetaminophen and the cyclooxygenase-3 puzzle: sorting out facts, fictions, and uncertainties. J Pharmacol Exp Ther 2005;315:1-7. (Pubitemid 41380491)
7. Loll PJ, Picot D, Ekabo O, et al. Synthesis and use of iodinated nonsteroidal antiinflammatory drug analogs as crystallographic probes of the prostaglandin H2synthase cyclooxygenase active site. Biochemistry 1996;35:7330-40. (Pubitemid 26191283)
8. Gierse JK, Koboldt CM, Walker MC, et al. Kinetic basis for selective inhibition of cyclo-oxygenases. Biochem J 1999;339:607-14. (Pubitemid 29243524)
9. Ouellet M, Percival MD. Mechanism of acetaminophen inhibition of cyclooxygenase isoforms. Arch Biochem Biophys 2001;387:273-80. (Pubitemid 32980589)
10. Boutaud O, Aronoff DM, Richardson JH, et al. Determinants of the cellular specificity of acetaminophen as an inhibitor of prostaglandin H(2) synthases. Proc Natl Acad Sci U S A 2002;99:7130-5. (Pubitemid 34526267)
11. Hinz B, Cheremina O, Brune K. Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man. FASEB J 2008;22:383-90. (Pubitemid 351225574)
12. Huntjens DR, Danhof M, Della Pasqua OE. Pharmacokinetic-pharmacodynamic correlations and biomarkers in the development of COX-2 inhibitors. Rheumatology (Oxford) 2005;44:846-59. (Pubitemid 41511177)
13. Reilly IA, FitzGerald GA. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood 1987;69:180-6. (Pubitemid 17007095)
14. Halliwell B, Gutteridge JM. The antioxidants of human extracellular fluids. Arch Biochem Biophys 1990;280:1-8. (Pubitemid 20196526)
15. 2 gene expression in a clinical model of acute inflammation. Pain 2007;129:279-86.
16. Boardman PL, Hart FD. Clinical measurement of the anti-inflammatory effects of salicylates in rheumatoid arthritis. BMJ 1967;4:264-8.
17. Ring EF, Collins AJ, Bacon PA, et al. Quantitation of thermography in arthritis using multi-isothermal analysis. II. Effect of nonsteroidal anti-inflammatory therapy on the thermographic index. Ann Rheum Dis 1974;33:353-6.
18. Seppälä E, Nissilä M, Isomäki H, et al. Comparison of the effects of different anti-inflammatory drugs on synovial fluid prostanoid concentrations in patients with rheumatoid arthritis. Clin Rheumatol 1985;4:315-20. (Pubitemid 16243508)
19. Skjelbred P, Løkken P. Paracetamol versus placebo: effects on post-operative course. Eur J Clin Pharmacol 1979;15:27-33. (Pubitemid 9235752)
20. Bjørnsson GA, Haanaes HR, Skoglund LA. A randomized, double-blind crossover trial of paracetamol 1000 mg four times daily vs ibuprofen 600 mg: effect on swelling and other postoperative events after third molar surgery. Br J Clin Pharmacol 2003;55:405-12. (Pubitemid 36535372)
21. Ferreira SH, Lorenzetti BB, Correa FM. Blockade of central and peripheral generation of prostaglandins explains the antialgic effect of aspirin like drugs. Pol J Pharmacol Pharm 1978;30:133-40. (Pubitemid 8364638)
22. Honoré P, Buritova J, Besson JM. Aspirin and acetaminophen reduced both Fos expression in rat lumbar spinal cord and inflammatory signs produced by carrageenin inflammation. Pain 1995;63:365-75.
23. Smith CJ, Zhang Y, Koboldt CM, et al. Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc Natl Acad Sci U S A 1998;95:13313-18. (Pubitemid 28509568)
24. Cannon CP, Curtis SP, FitzGerald GA, et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2006;368:1771-81. (Pubitemid 44739003)
25. Hinz B, Dormann H, Brune K. More pronounced inhibition of cyclooxygenase 2, increase in blood pressure, and reduction of heart rate by treatment with diclofenac compared with celecoxib and rofecoxib. Arthritis Rheum 2006;54:282-91. (Pubitemid 43122213)
26. O'Brien WF, Krammer J, O'Leary TD, et al. The effect of acetaminophen on prostacyclin production in pregnant women. Am J Obstet Gynecol 1993;168:1164-9. (Pubitemid 23122166)
27. Grèen K, Drvota V, Vesterqvist O. Pronounced reduction of in vivo prostacyclin synthesis in humans by acetaminophen (paracetamol). Prostaglandins 1989;37:311-15. (Pubitemid 19117858)
28. Walsh SW. Preeclampsia: an imbalance in placental prostacyclin and thromboxane production. Am J Obstet Gynecol 1985;152:335-40. (Pubitemid 15049763)
29. Noris M, Perico N, Remuzzi G. Mechanisms of disease: pre-eclampsia. Nat Clin Pract Nephrol 2005;1:98-114; quiz 120.
30. Zelop CM. Is it time to re-evaluate our use of acetaminophen in certain sub-groups of pregnant women? J Matern Fetal Neonatal Med 2008;21:761-2.
31. Rebordosa C, Zelop CM, Kogevinas M, et al. Use of acetaminophen during pregnancy and risk of preeclampsia, hypertensive and vascular disorders: a birth cohort study. J Matern Fetal Neonatal Med 2010;23:371-8.
32. McAdam BF, Catella-Lawson F, Mardini IA, et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A 1999;96:272-7. (Pubitemid 29036089)
33. Hinz B, Brune K. Can drug removals involving cyclooxygenase-2 inhibitors be avoided? A plea for human pharmacology. Trends Pharmacol Sci 2008;29:391-7.
34. García Rodríguez LA, Tacconelli S, Patrignani P. Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal antiinflammatory drugs in the general population. J Am Coll Cardiol 2008;52:1628-36.
35. Forman JP, Stampfer MJ, Curhan GC. Non-narcotic analgesic dose and risk of incident hypertension in US women. Hypertension 2005;46:500-7. (Pubitemid 41376829)
36. Chan AT, Manson JE, Albert CM, et al. Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation 2006;113:1578-87. (Pubitemid 43739417)
37. Sudano I, Flammer AJ, Périat D, et al. Acetaminophen increases blood pressure in patients with coronary artery disease. Circulation 2010;122:1789-96.
38. Mielke CH Jr. Comparative effects of aspirin and acetaminophen on hemostasis. Arch Intern Med 1981;141:305-10.
39. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001;345:1809-17.
40. Niemi TT, Backman JT, Syrjälä MT, et al. Platelet dysfunction after intravenous ketorolac or propacetamol. Acta Anaesthesiol Scand 2000;44:69-74. (Pubitemid 30016651)
41. Munsterhjelm E, Munsterhjelm NM, Niemi TT, et al. Dose-dependent inhibition of platelet function by acetaminophen in healthy volunteers. Anesthesiology 2005;103:712-17. (Pubitemid 41415519)
42. Munsterhjelm E, Niemi TT, Syrjälä MT, et al. Propacetamol augments inhibition of platelet function by diclofenac in volunteers. Br J Anaesth 2003;91:357-62. (Pubitemid 37063351)
43. Munsterhjelm E, Niemi TT, Ylikorkala O, et al. Characterization of inhibition of platelet function by paracetamol and its interaction with diclofenac in vitro. Acta Anaesthesiol Scand 2005;49:840-6. (Pubitemid 40941902)
44. Peskar BM. On the synthesis of prostaglandins by human gastric mucosa and its modification by drugs. Biochim Biophys Acta 1977;487:307-14. (Pubitemid 8091075)
45. Konturek SJ, Obtulowicz W, Sito E, et al. Distribution of prostaglandins in gastric and duodenal mucosa of healthy subjects and duodenal ulcer patients: effects of aspirin and paracetamol. Gut 1981;22:283-9. (Pubitemid 11113622)
46. Lanza FL, Codispoti JR, Nelson EB. An endoscopic comparison of gastroduodenal injury with over-the-counter doses of ketoprofen and acetaminophen. Am J Gastroenterol 1998;93:1051-4. (Pubitemid 29080948)
47. Patrono C, Patrignani P, García Rodríguez LA. Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. J Clin Invest 2001;108:7-13. (Pubitemid 32634915)
48. García Rodríguez LA, Hernández-Díaz S. Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs. Epidemiology 2001;12:570-6. (Pubitemid 32762000)
49. Garcia Rodríguez LA, Hernández-Díaz S. The risk of upper gastrointestinal complications associated with nonsteroidal anti-inflammatory drugs, glucocorticoids, acetaminophen, and combinations of these agents. Arthritis Res 2001;3:98-101. (Pubitemid 32237035)
50. Rahme E, Barkun A, Nedjar H, et al. Hospitalizations for upper and lower GI events associated with traditional NSAIDs and acetaminophen among the elderly in Quebec, Canada. Am J Gastroenterol 2008;103:872-82. (Pubitemid 351501121)
51. Doherty M, Hawkey C, Goulder M, et al. A randomised controlled trial of ibuprofen, paracetamol or a combination tablet of ibuprofen/paracetamol in community-derived people with knee pain. Ann Rheum Dis 2011;70:1534-41.
52. Picado C. Mechanisms of aspirin sensitivity. Curr Allergy Asthma Rep 2006;6:198-202. (Pubitemid 43970986)
53. Jenkins C, Costello J, Hodge L. Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice. BMJ 2004;328:434.
54. Settipane RA, Schrank PJ, Simon RA, et al. Prevalence of cross-sensitivity with acetaminophen in aspirin-sensitive asthmatic subjects. J Allergy Clin Immunol 1995;96:480-5.